A connected watch receives an update, a supplier delivers a module, and a brand modifies a product after its first market launch. Who then holds the design evidence, component contract and change history? The EU’s new product liability directive must be transposed by 9 December 2026 and applies to products placed on the market or put into service after that date. It clarifies the treatment of software, digital components, related services and substantial modifications. For Swiss exporters in watchmaking, luxury goods and precision manufacturing, this is not a mass-market campaign. The opportunity becomes concrete when a launch, distributor or new integration calls for a clear record of responsibilities. This briefing explains how to map a product, assign evidence and sell a tightly scoped launch review . It keeps commercial preparation separate from legal advice and does not turn an EU reform into an automatic promise of compliance or market access. General analysis as at 7 August 2026. It is not legal advice, insurance advice or a judicial decision.
What does 9 December 2026 change for a Swiss exporter?
Directive (EU) 2024/2853 applies to products placed on the market or put into service after 9 December 2026, following national transposition. A Swiss exporter must check the target market, the EU operator, the product version and applicable national law. The date does not create automatic Swiss compliance.
The date draws a boundary through the portfolio. A product already sold and a new version are not necessarily treated alike. The file must preserve the decision, its source and the professional responsible for it.
Why do software and updates change the responsibility map?
Software may fall within the definition of a product or component, while an update, related service or substantial modification may affect the manufacturer’s control. A brand that authorises an integration or continues to provide updates should therefore document the role, version, dependency and safety decision.
- 1Design
- 2Composition
- 3Version
- 4After-sales
Which operators should appear in an exported product’s file?
The file should identify the manufacturer, component suppliers, importer, distributor, related service providers, update owners and any authorised representative or EU contact. It records who holds each item of evidence and who decides when the product changes after launch.
| Operator | Decision | Evidence |
|---|---|---|
| Brand | intended use and market launch | product file |
| Supplier | component conformity | specification and batch |
| Software provider | version and fix | release log |
| Importer | market entry | contract and traceability |
| After-sales | signal and modification | procedure and decision |
What first service can be bought before a European launch?
The first saleable service is a responsibility review for one reference or family: operators, components and software; contracts; versions; available evidence; planned modifications; and questions for legal counsel or the insurer. It does not certify that no defect exists and cannot guarantee distribution, cover or the outcome of a dispute.
The scope makes the work commercially usable. A brand can buy a decision-ready gap map without commissioning a portfolio-wide legal exercise. The specialist review remains separate and is triggered only where the evidence or contract requires it.
How can businesses with an imminent decision be found?
Qualified targets are preparing a post-December 2026 launch, adding a digital function, changing a component, opening an EU sales channel or renegotiating distribution terms. Product research, industry networks, legal and insurance partners, trade fairs and account-based contact should all point to a specific event.
Watchmaking alone is a narrow market. The same method can cover Swiss precision manufacturers exporting an identifiable product, without using tariff volatility as a claim of demand.
- 1Launch or modification
- 2Product and market defined
- 3Responsibility review
- 4Specialist validation
- 5Launch decision
- 6Operators and evidence assigned?
Which metrics show that a review speeds up a decision?
Useful metrics are operators assigned, components linked, contracts reviewed, versions identified, gaps closed before launch and questions escalated to the right specialist. Reference counts, catalogue value and campaign impressions do not show that a product is ready for market.
- Rolesvalue: operators assigned
- Evidencevalue: documents linked
- Contractsvalue: gaps addressed
- Launchvalue: decision validated
When does the service become recurring without creating needless audits?
The service becomes recurring when a new reference, update, supplier, substantial modification, distributor or after-sales signal changes the file. Every review must correspond to an event and produce a decision. A portfolio alone does not justify an automatic subscription or assumed monthly revenue.
Which authorities define this opportunity, and where does getfishnet stop?
EUR-Lex publishes Directive (EU) 2024/2853, its scope, definitions and the 9 December 2026 date; the European Commission explains the modernisation for software and new technologies; and national authorities transpose it. getfishnet qualifies acquisition, while competent specialists determine the legal, contractual and insurance effect.
The official addresses remain in the private source manifest. This public briefing names the authorities without external links. Any campaign must be reviewed as the target country’s transposition develops.
- File assignedvalue: specialist validation
- Gaps to closevalue: owners and dates
- Outside scopevalue: product or market unconfirmed
How can you check at no cost whether this export strategy fits your offer?
The free eligibility test compares your expertise, evidence, exporter market, capacity and acquisition challenge. It asks whether a tailored strategy can connect a 2026 launch to a saleable review. It does not guarantee compliance, insurance, market access, absence of liability, a new client or revenue.
The eligibility report dates and quantifies it, then tests whether it deserves action.
Reading the diagram. A disease contact only progresses after proof of origin, qualification of the relationship and control of the product concerned.
Text alternative. Telephone, prescriber or incoming request follow different proofs; missing consent causes documented exit.
How can the testing cycle reach a stable operating rhythm?
Relative benchmarks: D00 sets the rules of origin and termination of contact, D14 closes the preparation, W03 to W06 tests the scripts, consents, relationships of more than thirty-six months and ceilings per product, W07 to W08 arbitrator, then M03 stabilizes documented paths. Variances are recorded before any budget extension.
Gantt chart for the testing cycle — NON-EXHAUSTIVE DEMONSTRATION
Reading the diagram. The foundation secures the right to contact; exploration then measures the quality of requests before any channel stabilization.
Textual alternative. D00 sets consent, D14 audits scripts, W03–W06 tests provenance, W07–W08 cuts discrepancies, M03 maintains compliance.
What financial potential does the model make visible?
Model: 132 qualified conversations, 44 reviews and 26 new customers. Weighted average: 1 527 CHF; monthly total: 39 700 CHF. The projection concerns acquisitions agreed and allocated, without using the ceilings as margin or portfolio value. No national denominator is applied.
Breakdown of acquisitions — NON-EXHAUSTIVE DEMONSTRATION
The chart counts customers, not percentage points.
Reading the diagram. 26 acquisitions represent subscriptions preceded by a controlled origin and relationship; the size of a share does not prejudge either the documentary quality or the maintained value.
Text alternative. The circle distributes customers obtained after verifiable consent, never people simply called. Total: 26 customers, reread with the value specific to each channel.
How do customers, average monthly revenue, and recurring revenue correlate by channel?
| Channel explored | Customers | Average monthly revenue per customer | Monthly Recurring Channel Revenue |
|---|---|---|---|
| Natural and paid referencing | 4 | 1 300 CHF | 5 200 CHF |
| Telephone outreach | 3 | 1 600 CHF | 4 800 CHF |
| Voicemails | 2 | 900 CHF | 1 800 CHF |
| Email Campaigns | 4 | 1 200 CHF | 4 800 CHF |
| Social networks | 3 | 1 400 CHF | 4 200 CHF |
| Partners and prescribers | 3 | 2 000 CHF | 6 000 CHF |
| Events and webinars | 2 | 1 700 CHF | 3 400 CHF |
| Advertising retargeting | 1 | 1 100 CHF | 1 100 CHF |
| Strategic accounts and outbound outreach | 2 | 2 300 CHF | 4 600 CHF |
| Content and press relations | 2 | 1 900 CHF | 3 800 CHF |
| Total / weighted average | 26 | 1 527 CHF | 39 700 CHF |
The value is read again with the product, the applicable ceiling and the cost of controlling the provenance. The product customers × average income totals 39 700 CHF without promising performance.
Monthly recurring revenue by channel — NON-EXHAUSTIVE DEMONSTRATION
Reading the diagram. Compliant disease contacts, their converted volumes and the corresponding monthly income recompose 39 700 CHF without a value outside the table.
Alternative text. Each height associates an authorized channel, actual assigned customers, and the value specific to their product. Their addition exactly equals monthly 39 700 CHF.
How should acquisition cost be assessed before recurring revenue is scaled?
Arbitration adds proof of consent, script control, relationship data, call supervision and refusal handling and reports the charge to assigned customers. It compares legal origin, product concerned, ceiling, full cost, expected termination and service capacity then reduces any channel that weakens the proof.
Funnel to Retained Monthly Recurring Revenue — NON-EXHAUSTIVE DEMONSTRATION
Reading the diagram. disease contacts whose origin is demonstrated produce raw 39 700 CHF, then 34 142 CHF after maintaining at 86 %.
Text alternative. 132 conversations become 44 journals and 26 clients for disease contacts whose provenance is demonstrated. 39 700 CHF weighted to 86 % gives 34 142 CHF.
Financial limit. The 70 francs and the sixteen bonuses limit the remuneration; they give neither margin, nor number of contracts, nor maintenance. The 34 142 CHF remains a hypothesis, without reference value or forecast.
Which sources and related readings deepen this analysis?
Text references: Federal Office of Public Health, decision and rules applicable to intermediaries; monitoring activity report. The federal office describes ceilings and outreach, while consent and history remain evidence specific to the file. The addresses remain in the internal source register. Each topic retains a clear documentary boundary.
The ISA 2024 processes the status. The ICA 2022 processes the contract trace. The nLPD 2023 shows another prequalification of the contact and data.
CORRELATED READINGS — DYNAMIC MODULE
The thematic map will link rules 2024 of health insurance intermediaries to ISA for status, ICA for contract and nLPD for legality of contact data. The links remain governed without implying equivalence.
- See the insurance & brokerage market
- Explore all market readings
- Test the eligibility of your own window
The September deadline has passed; each origin of contact must always be able to be explained The report isolates the proof and the next action without reopening the 2024 rules of health insurance intermediaries.
The topic is broken down into entities, attributes, evidence, channels, costs and decision points. Institutions are cited in the text; no external resource interrupts the reading path.